AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7044069 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac (75 mg or 150 mg/day)
Number of subjects: 35
Study 7044069 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 35
Study 7044069 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac
Number of subjects: 35
Study 7044069 — intervention group
Group type: EXPERIMENTAL
Intervention: Neither
Number of subjects: 35
Study 30847828 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion, 150 mg twice daily
Number of subjects: 8034
Study 30847828 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline, 1 mg twice daily
Number of subjects: 8034
Study 30847828 — intervention group
Group type: COMPARATOR
Intervention: Nicotine patch, 21 mg/day with taper (active control)
Number of subjects: 8034
Study 30847828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8034
Study 29804407 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (EGb761) drops oral treatment (3 times/d, 80 mg each time)
Number of subjects: 57
Study 29804407 — intervention group
Group type: COMPARATOR
Intervention: Routine oxygen inhalation and appeasement treatment
Number of subjects: 57
Study 26829087 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based visual feedback trunk control training (SPVFTCT)
Number of subjects: 24
Study 26829087 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 24
Study 24130008 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferumoxytol (Group A)
Number of subjects: 34
Study 24130008 — intervention group
Group type: COMPARATOR
Intervention: Gadofosveset (Group B)
Number of subjects: 34
Study 24130008 — intervention group
Group type: EXPERIMENTAL
Intervention: Contemporaneous imaging
Number of subjects: 34
Study 22270698 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and Exercise (group DE, n = 16)
Number of subjects: 62
Study 22270698 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet only (group D, n = 15)
Number of subjects: 62
Study 22270698 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise only (group E, n = 15)
Number of subjects: 62
Study 22270698 — intervention group
Group type: COMPARATOR
Intervention: Control (group C, n = 16)
Number of subjects: 62
Study 22270698 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and Exercise (group DE)
Number of subjects: 62
Study 19282713 — intervention group
Group type: EXPERIMENTAL
Intervention: IVRA ketamine (0.1 mg/kg in 1 mL of normal saline)
Number of subjects: 40
Study 19282713 — intervention group
Group type: COMPARATOR
Intervention: Systemic ketamine (0.1 mg/kg in 1 mL of normal saline via peripheral IV)
Number of subjects: 40
Study 19282713 — intervention group
Group type: EXPERIMENTAL
Intervention: IVRA ketamine
Number of subjects: 40
Study 19282713 — intervention group
Group type: COMPARATOR
Intervention: Systemic ketamine
Number of subjects: 40
Study 17457158 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (1 g intravenously every 8 hours for 7 to 21 days)
Number of subjects: 100
Study 17457158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 17457158 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 100
Study 17380519 — intervention group
Group type: EXPERIMENTAL
Intervention: Deaf Heart Health Intervention (DHHI)
Number of subjects: 84
Study 17380519 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 84
Study 14715169 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative computer planner for total knee arthroplasty (TKA)
Number of subjects: 10
Study 11050257 — intervention group
Group type: COMPARATOR
Intervention: Conventional inpatient care
Number of subjects: 81
Study 11050257 — intervention group
Group type: EXPERIMENTAL
Intervention: Early discharge with home treatment supported by respiratory nurses
Number of subjects: 81
Study 8923568 — intervention group
Group type: EXPERIMENTAL
Intervention: Mecamylamine (0, 10, or 20 mg)
Number of subjects: 20
Study 8923568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1464339 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine (20 mg once a day for 4 weeks)
Number of subjects: 135
Study 6424517 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic TPN
Number of subjects: 21
Study 6424517 — intervention group
Group type: COMPARATOR
Intervention: Continuous TPN
Number of subjects: 21
Study 31048447 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent prescribing by advanced physiotherapy practitioners (APPs)
Number of subjects: 0
Study 31048447 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometers fitted for 7 days
Number of subjects: 0
Study 31048447 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus group and semistructured interviews
Number of subjects: 0
Study 31048447 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidated Standards of Reporting Trials diagram
Number of subjects: 0
Study 31048447 — intervention group
Group type: EXPERIMENTAL
Intervention: Descriptive analysis of the data
Number of subjects: 0
Study 31048447 — intervention group
Group type: EXPERIMENTAL
Intervention: Thematic analysis
Number of subjects: 0
Study 29571528 — intervention group
Group type: EXPERIMENTAL
Intervention: Incredible Years® Teacher Classroom Management Program (IY‐TCM) implemented with 45 teachers who participated in five full day training workshops and brief classroom consultation.
Number of subjects: 1192
Study 29571528 — intervention group
Group type: EXPERIMENTAL
Intervention: Incredible Years® Teacher Classroom Management Program (IY‐TCM) for students with elevated social‐behavioral difficulties.
Number of subjects: 1192
Study 29571528 — intervention group
Group type: COMPARATOR
Intervention: Control group of 46 teachers who did not receive the IY‐TCM intervention.
Number of subjects: 1192
Study 27349951 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 20% autologous serum eye drops (ASEs) with silicone-hydrogel soft contact lenses (SCLs)
Number of subjects: 21
Study 27349951 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous use of ASEs for 2 weeks after SCLs removal
Number of subjects: 21
Study 27349951 — intervention group
Group type: COMPARATOR
Intervention: No continuous use of ASEs for 2 weeks after SCLs removal
Number of subjects: 21
Study 25247972 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphic indicating the site of pain
Number of subjects: 226
Study 25247972 — intervention group
Group type: COMPARATOR
Intervention: Text history only
Number of subjects: 226
Study 21928868 — intervention group
Group type: EXPERIMENTAL
Intervention: High level of drinking restraint (bogus feedback)
Number of subjects: 60
Study 21928868 — intervention group
Group type: COMPARATOR
Intervention: Low level of drinking restraint (bogus feedback)
Number of subjects: 60
Study 19396774 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract associated with hyaluronic acid ophthalmic solution (GB‐HA)
Number of subjects: 60
Study 19396774 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid ophthalmic solution (HA) alone
Number of subjects: 60
Study 17496391 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 49
Study 17496391 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ambulatory peritoneal dialysis (CAPD)
Number of subjects: 49
Study 17496391 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful kidney transplantation
Number of subjects: 49
Study 17496391 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 49
Study 15829474 — intervention group
Group type: EXPERIMENTAL
Intervention: Original online, interactive smoking cessation program
Number of subjects: 11969
Study 15829474 — intervention group
Group type: COMPARATOR
Intervention: Modified smoking cessation program
Number of subjects: 11969
Study 15829474 — intervention group
Group type: EXPERIMENTAL
Intervention: Original program (specific to smokers in contemplation stage)
Number of subjects: 11969
Study 15829474 — intervention group
Group type: COMPARATOR
Intervention: Modified program (specific to smokers in contemplation stage)
Number of subjects: 11969
Study 15829474 — intervention group
Group type: EXPERIMENTAL
Intervention: Original program (specific to smokers in precontemplation stage)
Number of subjects: 11969
Study 15829474 — intervention group
Group type: COMPARATOR
Intervention: Modified program (specific to smokers in precontemplation stage)
Number of subjects: 11969
Study 15829474 — intervention group
Group type: EXPERIMENTAL
Intervention: Original program (specific to smokers in preparation stage)
Number of subjects: 11969
Study 15829474 — intervention group
Group type: COMPARATOR
Intervention: Modified program (specific to smokers in preparation stage)
Number of subjects: 11969
Study 11777719 — intervention group
Group type: EXPERIMENTAL
Intervention: Honan balloon compression for 10 minutes after peribulbar anesthesia
Number of subjects: 50
Study 11777719 — intervention group
Group type: COMPARATOR
Intervention: No balloon compression after peribulbar anesthesia
Number of subjects: 50
Study 10099052 — intervention group
Group type: EXPERIMENTAL
Intervention: Pidotimod (800 mg once a day for 90 days)
Number of subjects: 49
Study 10099052 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical to pidotimod)
Number of subjects: 49
Study 10099052 — intervention group
Group type: EXPERIMENTAL
Intervention: Pidotimod
Number of subjects: 49
Study 10099052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 8088489 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 0.2 g intravenously b.i.d. + Metronidazole 0.5 g intravenously t.i.d.
Number of subjects: 57
Study 8088489 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin 2 g intravenously t.i.d. + Doxycycline 0.1 g b.i.d.
Number of subjects: 57
Study 2492066 — intervention group
Group type: EXPERIMENTAL
Intervention: Probabilities group
Number of subjects: 24
Study 2492066 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 24
Study 31610885 — intervention group
Group type: EXPERIMENTAL
Intervention: VBT + CT
Number of subjects: 4602
Study 31610885 — intervention group
Group type: COMPARATOR
Intervention: WPRT
Number of subjects: 4602
Study 31610885 — intervention group
Group type: COMPARATOR
Intervention: EBRT
Number of subjects: 4602
Study 29202852 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education intervention (six sessions)
Number of subjects: 200
Study 29202852 — intervention group
Group type: COMPARATOR
Intervention: Standard of care nutrition lecture (control)
Number of subjects: 200
Study 25737571 — intervention group
Group type: EXPERIMENTAL
Intervention: Home ventilator software (AHINIV)
Number of subjects: 10
Study 25737571 — intervention group
Group type: COMPARATOR
Intervention: Polysomnographic assessment (AHIPSG)
Number of subjects: 10
Study 24423701 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 1116
Study 24423701 — intervention group
Group type: COMPARATOR
Intervention: All respondents
Number of subjects: 1116
Study 22946636 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter with contact force measurement capabilities
Number of subjects: 50
Study 22946636 — intervention group
Group type: COMPARATOR
Intervention: Standard 3.5‐mm open‐irrigated‐tip catheter
Number of subjects: 50
Study 19229660 — intervention group
Group type: EXPERIMENTAL
Intervention: RYGBP
Number of subjects: 21
Study 17393127 — intervention group
Group type: EXPERIMENTAL
Intervention: mRCT
Number of subjects: 20
Study 14988283 — intervention group
Group type: EXPERIMENTAL
Intervention: Group care
Number of subjects: 120
Study 14988283 — intervention group
Group type: COMPARATOR
Intervention: Individual care (Control)
Number of subjects: 120
Study 12808272 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium soy sauce and miso (25% and 20% lower in salt content than common soy sauce and miso)
Number of subjects: 64
Study 12808272 — intervention group
Group type: COMPARATOR
Intervention: Control group (common soy sauce and miso)
Number of subjects: 64
Study 10343589 — intervention group
Group type: EXPERIMENTAL
Intervention: DIEP flap with sensory nerve repair
Number of subjects: 4
Study 10343589 — intervention group
Group type: COMPARATOR
Intervention: DIEP flap without nerve repair
Number of subjects: 4
Study 10343589 — intervention group
Group type: COMPARATOR
Intervention: Free TRAM flap without nerve repair
Number of subjects: 4
Study 7495249 — intervention group
Group type: EXPERIMENTAL
Intervention: MUFAs-enriched diets
Number of subjects: 0
Study 7495249 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental antioxidants (probucol and vitamin E)
Number of subjects: 0
Study 7495249 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary saturated fat reduction
Number of subjects: 0
Study 7495249 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary saturated fat replacement (MUFAs vs carbohydrates)
Number of subjects: 0
Study 2031201 — intervention group
Group type: EXPERIMENTAL
Intervention: FAC plus lonidamine (600 mg orally daily three times a day)
Number of subjects: 265
Study 2031201 — intervention group
Group type: COMPARATOR
Intervention: FAC (standard therapy)
Number of subjects: 265
Study 2031201 — intervention group
Group type: EXPERIMENTAL
Intervention: FAC plus lonidamine
Number of subjects: 265
Study 7016247 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated haemagglutination assay using Treponema pallidum antigen (AMHA‐TP)
Number of subjects: 330163
Study 7016247 — intervention group
Group type: COMPARATOR
Intervention: Fluorescent treponemal antibody‐absorption (FTA‐ABS) test
Number of subjects: 330163
Study 7016247 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat AMHA‐TP tests
Number of subjects: 330163
Study 31131640 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatic yoga and meditation (SYM) intervention, twice a week for 8 weeks for 1.5 hours, with home program and journaling.
Number of subjects: 10
Study 31131640 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatic yoga and meditation (SYM) intervention.
Number of subjects: 10
Study 28257436 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based cognitive flexibility training (58 half-hour sessions over 12 weeks)
Number of subjects: 97
Study 28257436 — intervention group
Group type: COMPARATOR
Intervention: Mock training (active control)
Number of subjects: 97
Study 28257436 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 97
Study 28257436 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based cognitive flexibility training
Number of subjects: 97
Study 28257436 — intervention group
Group type: COMPARATOR
Intervention: Active control and waiting list control
Number of subjects: 97
Study 27815483 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous Serum (AS) eye drops
Number of subjects: 24
Study 27815483 — intervention group
Group type: COMPARATOR
Intervention: Artificial Tear (AT) therapy
Number of subjects: 24
Study 24979446 — intervention group
Group type: EXPERIMENTAL
Intervention: Once‐daily oral tenofovir disoproxil fumarate (TDF) or FTC‐TDF
Number of subjects: 1522
Study 24979446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1522
Study 24979446 — intervention group
Group type: EXPERIMENTAL
Intervention: Once‐daily oral tenofovir-based PrEP
Number of subjects: 1522
Study 22653255 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate high-protein diet
Number of subjects: 307
Study 22653255 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 307
Study 19270357 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane preconditioning (1.0 minimum alveolar concentration end-tidal, approximately 1.1% to 1.2%) administered for 30 min followed by a 15 min washout period before CPB.
Number of subjects: 30
Study 19270357 — intervention group
Group type: COMPARATOR
Intervention: Control group (no isoflurane inhalation).
Number of subjects: 30
Study 17479540 — intervention group
Group type: COMPARATOR
Intervention: Metformin hydrochloride extended-release (MXR) 1000 mg single dose
Number of subjects: 42
Study 17479540 — intervention group
Group type: COMPARATOR
Intervention: Metformin hydrochloride extended-release (MXR) 1000 mg/d for 9 days
Number of subjects: 42
Study 17479540 — intervention group
Group type: COMPARATOR
Intervention: Metformin hydrochloride immediate-release (MIR) 1000 mg single dose
Number of subjects: 42
Study 17479540 — intervention group
Group type: COMPARATOR
Intervention: Metformin hydrochloride immediate-release (MIR) 1000 mg/d for 14 days
Number of subjects: 42
Study 14766692 — intervention group
Group type: EXPERIMENTAL
Intervention: McCoy straight blade laryngoscope
Number of subjects: 40
Study 14766692 — intervention group
Group type: COMPARATOR
Intervention: Miller curved blade laryngoscope
Number of subjects: 40
Study 12119202 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg per day)
Number of subjects: 11
Study 12119202 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg per day)
Number of subjects: 11
Study 12119202 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 11
Study 9402378 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir plus IVIG
Number of subjects: 56
Study 9402378 — intervention group
Group type: COMPARATOR
Intervention: IVIG alone
Number of subjects: 56
Study 8496328 — intervention group
Group type: EXPERIMENTAL
Intervention: GH therapy (0.125 IU/kg.week for the first 4 weeks and subsequently at 0.25 IU/kg.week for 1 year)
Number of subjects: 12
Study 8496328 — intervention group
Group type: EXPERIMENTAL
Intervention: GH therapy
Number of subjects: 12
Study 8496328 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 12
Study 2879882 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-blind placebo over a 2-week period
Number of subjects: 20
Study 2879882 — intervention group
Group type: COMPARATOR
Intervention: Double-blind placebo over an 8-week period
Number of subjects: 20
Study 31230988 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement System Impairment-Based classification treatment
Number of subjects: 0
Study 31230988 — intervention group
Group type: COMPARATOR
Intervention: Control group (other forms of exercise)
Number of subjects: 0
Study 31393414 — intervention group
Group type: EXPERIMENTAL
Intervention: Low to moderate intensity exercise program (LMIEP)
Number of subjects: 69
Study 31393414 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise program (MICEP)
Number of subjects: 69
Study 31393414 — intervention group
Group type: COMPARATOR
Intervention: Non-exercised group (Control)
Number of subjects: 69
Study 28006108 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitoxin 0.1 mg daily for 28 days
Number of subjects: 24
Study 28006108 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitoxin 0.05 mg daily for 28 days
Number of subjects: 24
Study 28006108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 26449209 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (1 mA for 10 min)
Number of subjects: 19
Study 26449209 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS (1 mA for 10 min)
Number of subjects: 19
Study 26449209 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (10 min)
Number of subjects: 19
Study 24637543 — intervention group
Group type: EXPERIMENTAL
Intervention: EFV (efavirenz)
Number of subjects: 269
Study 24637543 — intervention group
Group type: COMPARATOR
Intervention: ATV/r (atazanavir-ritonavir)
Number of subjects: 269
Study 24637543 — intervention group
Group type: COMPARATOR
Intervention: ABC/3TC (abacavir-lamivudine)
Number of subjects: 269
Study 24637543 — intervention group
Group type: COMPARATOR
Intervention: TDF/FTC (tenofovir DF-emtricitabine)
Number of subjects: 269
Study 21926600 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony stimulating factor (250 μg/M)
Number of subjects: 130
Study 21926600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 19153503 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegvisomant therapy
Number of subjects: 469
Study 17300305 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope
Number of subjects: 20
Study 17300305 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 20
Study 15446658 — intervention group
Group type: EXPERIMENTAL
Intervention: Same visual field presentation of primes and targets
Number of subjects: 0
Study 15446658 — intervention group
Group type: EXPERIMENTAL
Intervention: Different visual field presentation of primes and targets
Number of subjects: 0
Study 11177147 — intervention group
Group type: EXPERIMENTAL
Intervention: Central venous catheters cultured for clinical suspicion of infection
Number of subjects: 260
Study 9764028 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized teaching plan with quarterly telephone calls for smoking cessation and diet reinforcement
Number of subjects: 0
Study 9764028 — intervention group
Group type: COMPARATOR
Intervention: Standardized teaching plan without telephone reinforcement
Number of subjects: 0
Study 9764028 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received standardized teaching plan
Number of subjects: 0
Study 9764028 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers vs nonsmokers
Number of subjects: 0
Study 7933823 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant hirudin (0.08 mg/kg)
Number of subjects: 20
Study 3234411 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 240 mg (60 mg q.i.d.)
Number of subjects: 33
Study 3234411 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol 200 mg (100 mg b.i.d.)
Number of subjects: 33
Study 3234411 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 33
Study 3234411 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 33
Study 2058318 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (S2-receptor blocker) with concurrent physiotherapy
Number of subjects: 0
Study 2058318 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy alone
Number of subjects: 0
Study 332188 — intervention group
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid combined with fentonium bromide (125 mg and 20 mg respectively, 3-4 capsules daily for 14 days)
Number of subjects: 30
Study 332188 — intervention group
Group type: COMPARATOR
Intervention: Biliary acid alone
Number of subjects: 30
Study 20535582 — intervention group
Group type: EXPERIMENTAL
Intervention: Dixiong Decoction
Number of subjects: 46
Study 20535582 — intervention group
Group type: COMPARATOR
Intervention: Control group (commonly used herbal decoction)
Number of subjects: 46